Safety Alerts & Recalls

What does this mean?

Although the results from the SEAS study raise concerns about a possible link between Vytorin and cancer, several other larger ongoing trials do not show an increased risk of cancer with Vytorin. The FDA expects to release a final review about the safety of Vytorin in about 9 months. Based on the currently available information, the FDA has determined that patients should continue to take Vytorin or any other cholesterol-lowering drug.

FDA Is Reviewing Results From a Recent Clinical Trial of Vytorin

The FDA announced that it is reviewing the results of the "SEAS" trial - a clinical study that raised concerns about the risk of cancer in patients taking Vytorin compared with those given a placebo. Vytorin is a combination of two medications, simvastatin (Zocor) and ezetimibe (Zetia) and is used to lower cholesterol.

For more information please visit: more information here

Source: FDA
Publication Date: 2008-08-22
Last Updated: 2009-12-05

Visit the medication page for the following drugs:

Ezetimibe
Share your story Share your story! Tell us how MediGuard has helped you or someone you love. Mobile graphic Download the MediGuard Mobile App to manage your prescription and over-the-counter medications, for free. Registration Info Taking multiple medications puts you at risk for possible drug-drug interactions Registration Info Monitor the medical treatment of you and your loved ones.